你即將離開本站

並前往https://finance.yahoo.com/news/lynparza-olaparib-plus-abiraterone-reduced-220000452.html

LYNPARZA® (olaparib) plus Abiraterone ... - Yahoo Finance

PROpel Phase III trial results show clinically meaningful benefit in patients irrespective of homologous recombination repair gene mutations.

確定！ 回上一頁

查詢 「IARC group 3」的人也找了：

  1. IARC Group 3
    2.
  2. iarc分類
    3.
  3. iarc分類2021
    4.
  4. iarc分類2020
    5.
  5. IARC Group 1
    6.
  6. IARC 2A
    7.
  7. IARC 2B
    8.
  8. Carcinogen
    9.